This Biotech Stock Is Up 884% In 2021, But It Could Go Even Higher
When a biotech stock heads to the moon after releasing data on one of its drug programs, sometimes the party is just getting started.
And that might be exactly the case for Annovis Bio (NYSEMKT: ANVS), a biotech that's trying to tackle Alzheimer's disease and other neurodegenerative disorders. It's no secret that Alzheimer's is among the most challenging conditions to make drugs for. So, when the company let the world know that its lead program was showing convincing signs of being effective, the market rejoiced. Many others have failed where Annovis now intends to succeed -- but are things different this time, and can new investors benefit?
Image source: Getty Images.
Source Fool.com
